Donald S. Kaufman

8.5k citations

120 papers · 6.4k indexed · 2 hit papers · h-index 36

Surgery top 0.5%
Urology top 0.1%
Oncology top 2%
Pulmonary and Respiratory Medicine top 2%
Molecular Biology top 10%

Co-authors: William U. Shipley Anthony L. Zietman Adam S. Feldman Niall M. Heney Alex F. Althausen Philip W. Kantoff William Oh Jason A. Efstathiou
Topics: Bladder and Urothelial Cancer Treatments (78 papers)Urinary and Genital Oncology Studies (67 papers)Urological Disorders and Treatments (39 papers)
Cited by: Urology Surgery Oncology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: United States Canada Norway

In The Last Decade

Donald S. Kaufman

116 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bladder cancer

2009 812 citations Donald S. Kaufman, William U. Shipley et al. profile →
Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233

2014 294 citations Raymond H. Mak, Daniel Hunt et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Donald S. Kaufman

Since Specialization

Citations

This map shows the geographic impact of Donald S. Kaufman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald S. Kaufman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald S. Kaufman more than expected).

Fields of papers citing papers by Donald S. Kaufman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald S. Kaufman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald S. Kaufman. The network helps show where Donald S. Kaufman may publish in the future.

Co-authorship network of co-authors of Donald S. Kaufman

This figure shows the co-authorship network connecting the top 25 collaborators of Donald S. Kaufman. A scholar is included among the top collaborators of Donald S. Kaufman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald S. Kaufman. Donald S. Kaufman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233breakdown → 2014 ·Journal of Clinical Oncology ·Raymond H. Mak,Daniel Hunt,William U. Shipley,Jason A. Efstathiou,William Tester,Michael P. Hagan,Donald S. Kaufman,Niall M. Heney,Anthony L. Zietman	294
2	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma 2013 ·Clinical Genitourinary Cancer ·Benjamin L. Maughan,Neeraj Agarwal,Syed A. Hussain,Kenneth M. Boucher,Hans von der Maase,Donald S. Kaufman,Vito Lorusso,Malcolm J. Moore,Matthew D. Galsky,Guru Sonpavde	6
3	Case 9-2012 2012 ·New England Journal of Medicine ·Donald S. Kaufman,Anthony L. Zietman,W. Scott McDougal,Douglas M. Dahl,Mukesh G. Harisinghani,Chin‐Lee Wu	1
4	Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience 2011 ·European Urology ·Jason A. Efstathiou,Daphna Y. Spiegel,William U. Shipley,Niall M. Heney,Donald S. Kaufman,Andrzej Niemierko,John J. Coen,(unknown),Jonathan J. Paly,Francis J. McGovern,Anthony L. Zietman	293
5	Phase II study of sunitinib in men with advanced prostate cancer 2009 ·Annals of Oncology ·M. Dror Michaelson,Meredith M. Regan,William Oh,Donald S. Kaufman,(unknown),(unknown),Beverly Spicer,(unknown),Philip W. Kantoff,Matthew Smith	123
6	Bladder preservation: optimizing radiotherapy and integrated treatment strategies 2008 ·British Journal of Urology ·Raymond H. Mak,Anthony L. Zietman,Niall M. Heney,Donald S. Kaufman,William U. Shipley	33
7	Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer 2007 ·Journal of Clinical Oncology ·M. Dror Michaelson,Donald S. Kaufman,Hang Lee,Francis J. McGovern,Philip W. Kantoff,Mary Anne Fallon,Joel S. Finkelstein,Matthew R. Smith	235
8	Case 6-2007 2007 ·New England Journal of Medicine ·Donald S. Kaufman,Mansi A. Saksena,Robert H. Young,Shahin Tabatabaei	1
9	Bladder-sparing approaches to invasive disease 2006 ·World Journal of Urology ·Jason A. Efstathiou,Anthony L. Zietman,Donald S. Kaufman,Niall M. Heney,John J. Coen,William U. Shipley	16
10	Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer 2006 ·Urology ·Henry Tsai,Matthew S. Katz,John J. Coen,Anthony L. Zietman,Donald S. Kaufman,William U. Shipley	26
11	Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate 2004 ·Annals of Oncology ·Miah Hiang Tay,Donald S. Kaufman,Meredith M. Regan,(unknown),Daniel J. George,Philip G. Febbo,Judith Manola,Mitchell R. Smith,I.D. Kaplan,Philip W. Kantoff,William Oh	22
12	RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy 2003 ·International Journal of Radiation OncologyBiologyPhysics ·Michael P. Hagan,Kathryn Winter,Donald S. Kaufman,Zev Wajsman,Anthony L. Zietman,N.M. Heney,Leonard M. Toonkel,Christopher U. Jones,John D. Roberts,William U. Shipley	152
13	A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients 2002 ·Cancer Investigation ·William Oh,Judith Manola,Daniel J. George,(unknown),(unknown),Stephanie Morrissey,(unknown),Donald S. Kaufman,Charles L. Shapiro,Philip W. Kantoff,Matthew R. Smith	3
14	Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder 2001 ·Urology ·Anthony L. Zietman,Joseph A. Grocela,Elizabeth M Zehr,Donald S. Kaufman,Robert H. Young,Alex F. Althausen,Niall M. Heney,William U. Shipley	111
15	AN ORGAN-PRESERVING APPROACH TO MUSCLE-INVADING TRANSITIONAL CELL CANCER OF THE BLADDER 2001 ·Hematology/Oncology Clinics of North America ·Adam S. Brown,Anthony L. Zietman,William U. Shipley,Donald S. Kaufman	7
16	The Impact of 5-Fluorouracil and Intraoperative Electron Beam Radiation Therapy on the Outcome of Patients With Locally Advanced Primary Rectal and Rectosigmoid Cancer 1998 ·Annals of Surgery ·Bruce M. Nakfoor,Christopher G. Willett,Paul C. Shellito,Donald S. Kaufman,William J. Daly	55
17	Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. 1998 ·Journal of Clinical Oncology ·William U. Shipley,Kathryn Winter,Donald S. Kaufman,W. Robert Lee,N.M. Heney,William Tester,Bryan Donnelly,Peter Venner,Cirilo Pérez,(unknown),Reuben S. Doggett,Lawrence D. True	364
18	Invasive bladder cancer: Treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation 1997 ·International Journal of Radiation OncologyBiologyPhysics ·William U. Shipley,Anthony L. Zietman,Donald S. Kaufman,Alex F. Althausen,Niall M. Heney	34
19	Postoperative radiation therapy for high-risk colon carcinoma. 1993 ·Journal of Clinical Oncology ·Christopher G. Willett,Claire Y. Fung,Donald S. Kaufman,Jimmy T. Efird,Paul C. Shellito	61
20	Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. 1991 ·Journal of Clinical Oncology ·Claire Y. Fung,William U. Shipley,Robert H. Young,Pamela P. Griffin,Karen Convery,Donald S. Kaufman,Alex F. Althausen,Niall M. Heney,George R. Prout	67

About Donald S. Kaufman

Donald S. Kaufman is a scholar working on Urology, Surgery and Biotechnology, having authored 120 papers that have together received 6.4k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (78 papers), Urinary and Genital Oncology Studies (67 papers) and Urological Disorders and Treatments (39 papers). The work is most often cited by research in Urology (2.0k citations), Surgery (4.5k citations) and Oncology (1.5k citations). Donald S. Kaufman has collaborated with scholars based in United States, Canada and Norway. Frequent co-authors include William U. Shipley, Anthony L. Zietman, Adam S. Feldman, Niall M. Heney, Alex F. Althausen, Philip W. Kantoff, William Oh, Jason A. Efstathiou, N.M. Heney and Francis J. McGovern. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact